Jennifer S Read1, Yanling Huo2, Kunjal Patel3, Marcia Mitchell4, Gwendolyn B Scott5. 1. Pediatric, Adolescent, and Maternal AIDS Branch, Center for Research for Mothers and Children, National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland. 2. Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts. 3. Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts. 4. Department of Pediatrics, Jackson Memorial Hospital, Miami, Florida. 5. Department of Pediatrics, University of Miami Miller School of Medicine, Miami, Florida.
Abstract
BACKGROUND: Infant laboratory abnormalities have been associated with exposure to antiretrovirals and to trimethoprim/sulfamethoxazole (TMP/SMX). METHODS: We analyzed data from International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) Protocol P1025, a prospective cohort study of human immunodeficiency virus type 1 (HIV)-infected women and their infants. Live-born, singleton, HIV-uninfected infants with at least 6 months of follow-up who represented the first pregnancy on study of HIV-infected mothers with at least 1 prenatal visit, CD4 count, and viral load during pregnancy and who used at least 1 antiretroviral during pregnancy were eligible for inclusion in this analysis. RESULTS: The study population comprised 1524 infants. During the first 6 months of life, 7.4% of laboratory serious adverse events (SAEs) were related to glucose, 7.2% were related to hemoglobin, 8.7% were related to absolute neutrophil count, and 4.0% were related to total lymphocyte count. The likelihood of laboratory SAEs decreased with increasing age for hemoglobin, absolute neutrophil count, and glucose. Infant preterm birth and current receipt of antiretroviral(s) were the factors with the strongest associations with laboratory SAEs. CONCLUSIONS: The overall frequency of laboratory SAEs was low and decreased with age. Preterm infants are at higher risk of hemoglobin- and total lymphocyte count-related SAEs. Published by Oxford University Press on behalf of the Pediatric Infectious Diseases Society 2012.
BACKGROUND:Infantlaboratory abnormalities have been associated with exposure to antiretrovirals and to trimethoprim/sulfamethoxazole (TMP/SMX). METHODS: We analyzed data from International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) Protocol P1025, a prospective cohort study of human immunodeficiency virus type 1 (HIV)-infectedwomen and their infants. Live-born, singleton, HIV-uninfectedinfants with at least 6 months of follow-up who represented the first pregnancy on study of HIV-infected mothers with at least 1 prenatal visit, CD4 count, and viral load during pregnancy and who used at least 1 antiretroviral during pregnancy were eligible for inclusion in this analysis. RESULTS: The study population comprised 1524 infants. During the first 6 months of life, 7.4% of laboratory serious adverse events (SAEs) were related to glucose, 7.2% were related to hemoglobin, 8.7% were related to absolute neutrophil count, and 4.0% were related to total lymphocyte count. The likelihood of laboratory SAEs decreased with increasing age for hemoglobin, absolute neutrophil count, and glucose. Infant preterm birth and current receipt of antiretroviral(s) were the factors with the strongest associations with laboratory SAEs. CONCLUSIONS: The overall frequency of laboratory SAEs was low and decreased with age. Preterm infants are at higher risk of hemoglobin- and total lymphocyte count-related SAEs. Published by Oxford University Press on behalf of the Pediatric Infectious Diseases Society 2012.
Authors: Kunjal Patel; David E Shapiro; Susan B Brogly; Elizabeth G Livingston; Alice M Stek; Arlene D Bardeguez; Ruth E Tuomala Journal: J Infect Dis Date: 2010-04-01 Impact factor: 5.226
Authors: Marisa M Mussi-Pinhata; Maria Aparecida C Rego; Laura Freimanis; Fabiana M Kakehasi; Daisy Maria Machado; Edmundo M Cardoso; Jennifer S Read Journal: Pediatr Infect Dis J Date: 2007-11 Impact factor: 2.129
Authors: E S Machado; C B Hofer; T T Costa; S A Nogueira; R H Oliveira; T F Abreu; L A Evangelista; I F A Farias; R T C Mercadante; M F L Garcia; R C Neves; V M Costa; J S Lambert Journal: Sex Transm Infect Date: 2008-11-05 Impact factor: 3.519
Authors: Jose Ma Bellón Cano; Silvia Sánchez-Ramón; Luis Ciria; Juan Antonio León; Dolores Gurbindo; Claudia Fortuny; José Ma Bertrán; Jesús Ruiz Contreras; José-Tomás Ramos; Oscar Asensi; Antonio Mur; Rosa Resino; Ma Angeles Muñóz-Fernández Journal: Med Sci Monit Date: 2004-04-28
Authors: I Grosch-Woerner; K Puch; R F Maier; T Niehues; G Notheis; D Patel; S Casteleyn; C Feiterna-Sperling; S Groeger; D Zaknun Journal: HIV Med Date: 2008-01 Impact factor: 3.180
Authors: Claire L Townsend; Barbara A Willey; Mario Cortina-Borja; Catherine S Peckham; Pat A Tookey Journal: AIDS Date: 2009-02-20 Impact factor: 4.177
Authors: Ruth E Tuomala; David E Shapiro; Lynne M Mofenson; Yvonne Bryson; Mary Culnane; Michael D Hughes; M J O'Sullivan; Gwendolyn Scott; Alice M Stek; Diane Wara; Marc Bulterys Journal: N Engl J Med Date: 2002-06-13 Impact factor: 91.245
Authors: Risa M Hoffman; Erin Leister; Deborah Kacanek; David E Shapiro; Jennifer S Read; Yvonne Bryson; Judith S Currier Journal: J Acquir Immune Defic Syndr Date: 2013-08-15 Impact factor: 3.731
Authors: Paige L Williams; Yanling Huo; Richard Rutstein; Rohan Hazra; Kathryn Rough; Russell B Van Dyke; Ellen G Chadwick Journal: AIDS Patient Care STDS Date: 2018-02 Impact factor: 5.078